Actipulse Neuroscience develops high‑frequency transcranial magnetic stimulation (TMS) devices that deliver precise, deep cortical magnetic pulses to modulate neural activity in neurodegenerative and psychiatric disorders. The company conducts rigorous clinical trials, including a Phase 3 pivotal study for major depressive disorder, to provide clinicians with FDA‑compliant, non‑invasive neuromodulation tools that can be integrated into standard care.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for neurodegenerative and psychiatric disorders rely heavily on pharmacotherapy, which often provides limited efficacy and can cause significant side effects. Non‑invasive brain stimulation options are scarce, and existing devices lack the precision or clinical validation needed to become standard care.
Solution
Actipulse Neuroscience develops high‑frequency transcranial magnetic stimulation (TMS) devices that deliver focused magnetic pulses to modulate neural activity implicated in neurodegenerative and psychiatric conditions. By engineering protocols that engage multiple pathogenic mechanisms, the company aims to improve symptom control and disease progression without invasive surgery or systemic drugs. Actipulse conducts rigorous clinical trials, including a Phase 3 pivotal study for major depressive disorder, to generate robust efficacy and safety data. The technology is positioned to integrate into existing clinical workflows, offering clinicians a validated, non‑pharmacologic therapeutic option.
Target Audience
Primary customers are neurologists, psychiatrists, and academic research centers seeking FDA‑compliant, non‑invasive neuromodulation tools for treating neurodegenerative and psychiatric disorders.
Features
- High‑frequency magnetic pulse TMS hardware designed for precise, deep cortical targeting
- Programmable stimulation protocols that address several disease‑related neural pathways
- Clinical‑grade device meeting stringent safety and ethical standards
- Ongoing Phase 3 trial infrastructure with data collection and analysis pipelines
- Compatibility with standard clinical environments and electronic health record integration